CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled / 31 target
Drug / intervention
PM8002 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05918107
NCT05918107Phase 2CompletedOn Track (0.7/mo)Completion was 3mo ago
CompareCT.gov

Phase II Clinical Trial to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetic Characteristics of PM8002 Injection Combined With Standard Chemotherapy in the First-line Treatment of Subjects With Inoperable Malignant Mesothelioma

Biotheus Inc.·interventional·Posted Jun 26, 2023·Updated Jun 8, 2026

In Brief

A Phase 2 clinical trial evaluating PM8002, Pemetrexed, and 2 other interventions for MPM. Completed, enrolled 31 participants across 16 sites.

Detailed Summary

PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with pemetrexed and platinum as first line treatment for MPM.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMPM
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedJun 26, 2023
Enrollment StartAug 13, 2022
Primary CompletionMar 31, 2026
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 3.0 years ago

Arms & Interventions

PM8002+pemetrexed+platinumother

Subjects will be administered with PM8002 plus pemetrexed+platinum via intravenously (IV) Q3W for 4-6 cycles,followed by PM8002 until disease progression intolerable toxicity for a maximum of 2 years.

Drug: PM8002Drug: PemetrexedDrug: CisplatinDrug: Carboplatin

Interventions

PM8002drug

IV infusion

Pemetrexeddrug

IV infusion

Cisplatindrug

IV infusion

Carboplatindrug

IV infusion